Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CDC25A | P30304 | 2/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12592463 | 0.88 | CDC25A (0.58) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL9655485 | 0.87 | CDC25A (0.64) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL3420496 | 0.82 | MAPT (0.58) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL9180312 | 0.81 | DUSP3 (0.48) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL487582 | 0.81 | IDO1 (0.42) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL4725792 | 0.81 | APEX1 (0.44) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL5158684 | 0.81 | DUSP3 (0.42) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL8252760 | 0.81 | AURKA (0.46) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL5590298 | 0.80 | CDC25A (0.56) | MAPTTDP1IDO1ALDH1A1LMNA | |
| SCHEMBL13033957 | 0.77 | MAPT (0.61) | MAPTTDP1IDO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | claimed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | claimed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| EP-3858351-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS | LTT Bio-Pharma Co., Ltd. (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-20210130457-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC | 2021-05-06 | — | — | US | disclosed |
| US-10913795-B2 | Compositions and methods for antibody production | IMMUNOGEN, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2019113210-A1 | PHOSPHONIUM-BASED IONIC DRUG CONJUGATES | ANTHOS PARTNERS, LP (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190119374-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-2238968-B1 | Skin treatment fighting skin aging | HENKEL AG & CO KGAA (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2841169-B1 | HAIR PREPARATIONS COMPRISING HYDROXY-TERMINATED ORGANOPOLYSILOXANE(S) AND THICKENER(S) | HENKEL AG & CO KGAA (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-9801922-B2 | Compositions and methods of treating cancer | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2005019233-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1169466-A4 | SYNTHESIS OF 1,2,3,4-TETRAHYDROXYBENZENES AND 1,2,3-TRIHYDROXYBENZENES USING MYO-INOSITOL-1-PHOSPHATE SYNTHASE AND MYO-INOSITOL 2-DEHYDROGENASE | UNIV MICHIGAN STATE (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040209337-A1 | Synthesis of 1,2,3,4-tetrahydroxybenzenes from biomass-derived carbon | NATIONAL SCIENCE FOUNDATION | 2004-10-21 | — | — | US | disclosed |
| US-6750049-B1 | Synthesis of 1,2,3,4-tetrahydroxybenzenes and 1,2,3-trihydroxybenzenes using myo-inositol-1-phosphate synthase and myo-inositol 2-dehydrogenase | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2004-06-15 | — | — | US | disclosed |
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | disclosed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1169466-A1 | SYNTHESIS OF 1,2,3,4-TETRAHYDROXYBENZENES AND 1,2,3-TRIHYDROXYBENZENES USING MYO-INOSITOL-1-PHOSPHATE SYNTHASE AND MYO-INOSITOL 2-DEHYDROGENASE | Board of Trustees operating Michigan State University (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000056911-A1 | SYNTHESIS OF 1,2,3,4-TETRAHYDROXYBENZENES AND 1,2,3-TRIHYDROXYBENZENES USING MYO-INOSITOL-1-PHOSPHATE SYNTHASE AND MYO-INOSITOL 2-DEHYDROGENASE | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | SOD1, SOD3, APEX1 | MAPT 3245/4885TDP1 697/4885IDO1 2808/4885 |
| US-20190119374-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | TXNRD1, P4HB, CYBB | MAPT 3936/4885TDP1 4634/4885IDO1 2753/4885 |
| US-10913795-B2 | Compositions and methods for antibody production | TXNRD1, P4HB, CYBB | MAPT 3936/4885TDP1 4634/4885IDO1 2753/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 82/4885TDP1 1397/4885IDO1 853/4885 |
| US-20210130457-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | TXNRD1, P4HB, CYBB | MAPT 3936/4885TDP1 4634/4885IDO1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.